<p>Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - 获取免费报告) 的股价在周五交易中下跌了 2.6%。该股票最低交易价为$12.56，最后交易价为$12.96。在午盘交易中，共交易了 778,019 股，较平均交易量 1,396,707 股下降了 44%。该股票此前收盘价为$13.31。</p>
<h2>分析师设定新目标价</h2>
<p>几家券商最近对 PHAT 进行了评论。华尔街 Zen 在周六的研究报告中将 Phathom Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Phathom Pharmaceuticals 股票的 “卖出（d-）” 评级。一位投资分析师给予该股票 “强烈买入” 评级，四位分析师给予 “买入” 评级，一位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为$17.50。</p>
<p><strong>查看我们对 Phathom Pharmaceuticals 的最新股票分析</strong></p>
<h2>Phathom Pharmaceuticals 股票表现</h2>
<p>该公司的市值为 9.1938 亿美元，市盈率为-2.74，贝塔值为 0.43。该公司的 50 日简单移动平均线为$11.70，200 日简单移动平均线为$8.31。</p>
<h2>机构投资者对 Phathom Pharmaceuticals 的看法</h2>
<p>对冲基金最近买入和卖出了该股票的股份。Jacobs Levy Equity Management Inc.在第一季度收购了 Phathom Pharmaceuticals 的新股份，价值约为$3,738,000。GAMMA Investing LLC 在第一季度将其在 Phathom Pharmaceuticals 的持仓提高了 797.2%。GAMMA Investing LLC 现在拥有该公司 4,558 股股票，价值$29,000，此前在上个季度购买了额外的 4,050 股。Russell Investments Group Ltd.在第一季度购买了 Phathom Pharmaceuticals 的新股份，价值约为$262,000。US Bancorp DE 在第一季度将其在 Phathom Pharmaceuticals 的持股增加了 248.1%。US Bancorp DE 现在拥有该公司 23,763 股股票，价值$149,000，此前在上个季度收购了额外的 16,937 股。最后，Wellington Management Group LLP 在第一季度将其在 Phathom Pharmaceuticals 的持股增加了 47.6%。Wellington Management Group LLP 现在拥有该公司 200,690 股股票，价值$1,258,000，此前在上个季度收购了额外的 64,695 股。机构投资者和对冲基金持有该公司 99.01% 的股份。</p>
<h2>关于 Phathom Pharmaceuticals</h2>
<p>(获取免费报告)</p>
<p>Phathom Pharmaceuticals, Inc.是一家生物制药公司，专注于开发和商业化治疗胃肠疾病的药物。该公司在美国、欧洲和加拿大拥有一种研究性钾竞争性酸阻滞剂（P-CAB）的权利，该药物可以阻止胃酸分泌。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，而不是 Phathom Pharmaceuticals</li>
<li>现在值得购买的 3 只沃伦·巴菲特股票</li>
<li>这家 AI 芯片巨头可能是市场下一个大赢家</li>
<li>英国市场假期是什么？如何投资和交易</li>
<li>博通与 OpenAI 达成协议：为什么这对 AVGO 股票是一个巨大的胜利</li>
<li>便士股票适合你的投资组合吗？</li>
<li>机构正在推动 CrowdStrike 的下一轮上涨</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Phathom Pharmaceuticals 吗？</h2>
<p>在你考虑 Phathom Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Phathom Pharmaceuticals 并不在名单上。</p>
<p>虽然 Phathom Pharmaceuticals 目前在分析师中有 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PHAT

<p>Phathom Pharmaceuticals（纳斯达克代码：PHAT）股价下跌 2.6%，至 12.96 美元，交易量较平均水平下降 44%。分析师的评级各不相同，其中一位给予强烈买入，四位给予买入，一位持有，一位卖出。该股票的评级为适度买入，市场共识目标价为 17.50 美元。机构投资者持有该公司 99.01% 的股份，该公司专注于胃肠疾病的治疗。尽管近期股价下跌，一些分析师认为在 Phathom Pharmaceuticals 之外存在更好的投资机会</p>

<p>Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report)'s share price fell 2.6% during trading on Friday . The stock traded as low as $12.56 and last traded at $12.96. 778,019 shares were traded during mid-day trading, a decline of 44% from the average session volume of 1,396,707 shares. The stock had previously closed at $13.31.</p>
<div class="lb-trans"><p>Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - 获取免费报告) 的股价在周五交易中下跌了 2.6%。该股票最低交易价为$12.56，最后交易价为$12.96。在午盘交易中，共交易了 778,019 股，较平均交易量 1,396,707 股下降了 44%。该股票此前收盘价为$13.31。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several brokerages have recently commented on PHAT. Wall Street Zen raised Phathom Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $17.50.</p>
<div class="lb-trans"><p>几家券商最近对 PHAT 进行了评论。华尔街 Zen 在周六的研究报告中将 Phathom Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Phathom Pharmaceuticals 股票的 “卖出（d-）” 评级。一位投资分析师给予该股票 “强烈买入” 评级，四位分析师给予 “买入” 评级，一位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为$17.50。</p>
</div><p><strong>View Our Latest Stock Analysis on Phathom Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Phathom Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Phathom Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Phathom Pharmaceuticals 股票表现</h2>
</div><p>The company has a market cap of $919.38 million, a price-to-earnings ratio of -2.74 and a beta of 0.43. The business has a 50-day simple moving average of $11.70 and a 200-day simple moving average of $8.31.</p>
<div class="lb-trans"><p>该公司的市值为 9.1938 亿美元，市盈率为-2.74，贝塔值为 0.43。该公司的 50 日简单移动平均线为$11.70，200 日简单移动平均线为$8.31。</p>
</div><h2>Institutional Investors Weigh In On Phathom Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Phathom Pharmaceuticals 的看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. acquired a new stake in Phathom Pharmaceuticals in the 1st quarter valued at about $3,738,000. GAMMA Investing LLC raised its position in Phathom Pharmaceuticals by 797.2% in the 1st quarter. GAMMA Investing LLC now owns 4,558 shares of the company's stock valued at $29,000 after purchasing an additional 4,050 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Phathom Pharmaceuticals in the 1st quarter valued at about $262,000. US Bancorp DE increased its holdings in shares of Phathom Pharmaceuticals by 248.1% in the 1st quarter. US Bancorp DE now owns 23,763 shares of the company's stock valued at $149,000 after acquiring an additional 16,937 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Phathom Pharmaceuticals by 47.6% in the 1st quarter. Wellington Management Group LLP now owns 200,690 shares of the company's stock valued at $1,258,000 after acquiring an additional 64,695 shares during the last quarter. Institutional investors and hedge funds own 99.01% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近买入和卖出了该股票的股份。Jacobs Levy Equity Management Inc.在第一季度收购了 Phathom Pharmaceuticals 的新股份，价值约为$3,738,000。GAMMA Investing LLC 在第一季度将其在 Phathom Pharmaceuticals 的持仓提高了 797.2%。GAMMA Investing LLC 现在拥有该公司 4,558 股股票，价值$29,000，此前在上个季度购买了额外的 4,050 股。Russell Investments Group Ltd.在第一季度购买了 Phathom Pharmaceuticals 的新股份，价值约为$262,000。US Bancorp DE 在第一季度将其在 Phathom Pharmaceuticals 的持股增加了 248.1%。US Bancorp DE 现在拥有该公司 23,763 股股票，价值$149,000，此前在上个季度收购了额外的 16,937 股。最后，Wellington Management Group LLP 在第一季度将其在 Phathom Pharmaceuticals 的持股增加了 47.6%。Wellington Management Group LLP 现在拥有该公司 200,690 股股票，价值$1,258,000，此前在上个季度收购了额外的 64,695 股。机构投资者和对冲基金持有该公司 99.01% 的股份。</p>
</div><h2>About Phathom Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Phathom Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.</p>
<div class="lb-trans"><p>Phathom Pharmaceuticals, Inc.是一家生物制药公司，专注于开发和商业化治疗胃肠疾病的药物。该公司在美国、欧洲和加拿大拥有一种研究性钾竞争性酸阻滞剂（P-CAB）的权利，该药物可以阻止胃酸分泌。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Phathom Pharmaceuticals</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>This AI Chip Giant Could Be the Market’s Next Big Winner</li>
<li>What Are the U.K. Market Holidays? How to Invest and Trade</li>
<li>Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Institutions Are Fueling CrowdStrike’s Next Leg Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Phathom Pharmaceuticals</li>
<li>现在值得购买的 3 只沃伦·巴菲特股票</li>
<li>这家 AI 芯片巨头可能是市场下一个大赢家</li>
<li>英国市场假期是什么？如何投资和交易</li>
<li>博通与 OpenAI 达成协议：为什么这对 AVGO 股票是一个巨大的胜利</li>
<li>便士股票适合你的投资组合吗？</li>
<li>机构正在推动 CrowdStrike 的下一轮上涨</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Phathom Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Phathom Pharmaceuticals 吗？</h2>
</div><p>Before you consider Phathom Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Phathom Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Phathom Pharmaceuticals 并不在名单上。</p>
</div><p>While Phathom Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Phathom Pharmaceuticals 目前在分析师中有 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Phathom Pharmaceuticals（NASDAQ:PHAT）股价下跌 2.6% - 以下是原因